SN50 |
Catalog No.GC31642
One-Click Copy Product Info
|
SN50, el péptido inhibidor permeable a las células NF-κB.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 213546-53-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SN50, el péptido inhibidor permeable a las células NF-κB. Está compuesto por la región hidrofílica del péptido de señal del factor de crecimiento de fibroblastos de Kaposi como un motivo de translocación de membrana y una secuencia de localización nucelar derivada de la subunidad p50 de NF-κB[1].
SN50(20 µg/ml; 12 hs) podría inducir la diferenciación de la microglía en tipo M2 a través de la vía NF-κB. La microglía inducida por SN50 puede proteger a las neuronas de lesiones hipóxicas[2]. SN50 (25 µg/ml; 24 hs) podría inducir una diferenciación robusta de los GSCs, y las células pierden la motilidad neuroglobular, la invasividad y la insensibilidad al tratamiento tumorigenicidad de las células madre tumorales[4].
SN50(100µl,10,30,60µg/ml; i.p.;1h) atenuó la hipercoagulación alveolar y la inhibición de la fibrinólisis en el ARDS a través de la inhibición de la translocación NF-κB p65 [5]. SN50(1µM) protegió contra lesiones pulmonares inducidas por LPS en un pulmón de rata aislado al inhibir la translocación nuclear de NF-κB[6]. SN50 tópico (10µM; 12 días) supriomió la activación del factor nuclear-κB en las células locales y redujo la incidencia de defectos epiteliales/ulceración en ratones C57BL/6 que curan las córneas[7].
References:
[1]. Lin YZ, Yao SY,et al. Inhibition of nuclear translocation of transcription factor NF kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995;270(24):14255-8.
[2]. Chian CF, Chiang CH, et,al. Inhibitor of nuclear factor-κB, SN50, attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model. Transl Res. 2014 Mar;163(3):211-20. doi: 10.1016/j.trsl.2013.10.002. Epub 2013 Oct 12. PMID: 24646628.
[3]. Zhang L, Ren X, et,al. The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biol Ther. 2014 May;15(5):602-11. doi: 10.4161/cbt.28158. Epub 2014 Feb 20. PMID: 24557012; PMCID: PMC4026083.
[4]. Zhao K, Zhu BS, et,al. SN50 enhances the effects of LY294002 on cell death induction in gastric cancer cell line SGC7901. Arch Med Sci. 2013 Dec 30;9(6):990-8. doi: 10.5114/aoms.2013.39790. Epub 2013 Dec 26. PMID: 24482641; PMCID: PMC3902720.
[5]. Wu Y, Wang Y, et,al.SN50 attenuates alveolar hypercoagulation and fibrinolysis inhibition in acute respiratory distress syndrome mice through inhibiting NF-κB p65 translocation. Respir Res. 2020 May 27;21(1):130. doi: 10.1186/s12931-020-01372-6. PMID: 32460750; PMCID: PMC7251840.
[6]. Chian CF, Chiang CH, et,al. Inhibitor of nuclear factor-κB, SN50, attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model. Transl Res. 2014 Mar;163(3):211-20. doi: 10.1016/j.trsl.2013.10.002. Epub 2013 Oct 12. PMID: 24646628.
[7]. Saika S, Miyamoto T, et,al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. Am J Pathol. 2005 May;166(5):1393-403. doi: 10.1016/s0002-9440(10)62357-7. PMID: 15855640; PMCID: PMC1606394.
| Experimentos celulares [1]: | |
Líneas celulares | Células similares al tronco del glioma GSC11 y GSC23 |
Método de preparación | Las células se cultivaron en un medio que contenía 2% de B-27, 20 ng/mLde EGF y 20 ng/mL de β-FGF en presencia o ausencia de SN50 (25 µg/mL) durante veinticuatro horas. |
Condiciones de reacción | 25 µg/ml; 24 horas |
Áreas de aplicación | SN50 puede inducir la diferenciación de GSC. |
| Experimentos con animales [2]: | |
Modelos animales | Ratones Balb/c macho (8-12 semanas) |
Método de preparación | Los ratones fueron hechos por inhalación de 50 µl de lipopolisacárido (LPS) (4 mg/ml). A los ratones se les inyectó intraperitonealmente diferentes dos de SN50 1 h antes de la inhalación de LPS. |
Forma de dosificación | 100µl,10,30,60µg/ml; i.p.;1h |
Áreas de aplicación | SN50 inhibió las expresiones de TF y PAI-1 en mRNA y en niveles de proteínas en ratones con síndrome de dificultad respiratoria aguda (ARDS) inducido por LPS. |
References: | |
| Cas No. | 213546-53-3 | SDF | |
| Canonical SMILES | Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro | ||
| Formula | C129H230N36O29S | M.Wt | 2781.5 |
| Solubility | Water : ≥ 50 mg/mL (17.98 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 359.5 μL | 1.7976 mL | 3.5952 mL |
| 5 mM | 71.9 μL | 359.5 μL | 719 μL |
| 10 mM | 36 μL | 179.8 μL | 359.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)